Capsules d’une trentaine de minutes sur différents sujets reliés à la pharmacothérapie et la médecine fondée sur les preuves. Les hôtes et les invités discuteront de façon interactive dans chacun des épisodes des meilleures pratiques à adopter selon les preuves existantes dans la littérature et exposeront les risques et les bienfaits d’une conduite clinique dans un sujet donné. pharmascope.ca
Pharmascope
Claim This Podcastby Pharmascope
4.8(37 reviews)
55 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇨🇦
Podcast Overview
Capsules d’une trentaine de minutes sur différents sujets reliés à la pharmacothérapie et la médecine fondée sur les preuves. Les hôtes et les invités discuteront de façon interactive dans chacun des épisodes des meilleures pratiques à adopter selon les preuves existantes dans la littérature et exposeront les risques et les bienfaits d’une conduite clinique dans un sujet donné. pharmascope.ca
Language
🇫🇷
Publishing Since
7/23/2018
1 verified contact email on file for Pharmascope
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
June 6, 2026
Épisode 178 – Toujours des questions, parfois des réponses…
<p>Un nouvel épisode du Pharmascope est disponible! Dans ce 178e épisode, Nicolas, Olivier et Amélie tentent de pondre des réponses un tant soi peu intelligentes à vos excellentes questions. Nous discutons d’ajustement de lévothyroxine, du suivi des IECA/ARA, du rôle de la cariprazine et de l’impact des inhibiteurs du SGLT-2 sur le magnésium.  </p> <p>Les objectifs pour cet épisode sont les suivants:</p> <ul class="wp-block-list"> <li>Discuter des modalités d’ajustement de la lévothyroxine et de la déprescription potentielle de celle-ci</li> <li>Discuter des suivis de laboratoire suivant l’initiation d’un ARA ou d’un IECA</li> <li>Discuter des évidences portant sur l’utilisation de la cariprazine</li> <li>Discuter de l’impact des inhibiteurs du SGLT-2 sur le magnésium</li> </ul> <div style="height:78px" aria-hidden="true" class="wp-block-spacer"></div> <p><strong>Ressources pertinentes en lien avec l’épisode</strong></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/25266247/" target="_blank" rel="noreferrer noopener">Jonklaas J, et coll; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/37655789/" target="_blank" rel="noreferrer noopener">Van Uytfanghe K, et coll. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status. Thyroid. 2023 Sep;33(9):1013-1028.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/41941226/" target="_blank" rel="noreferrer noopener">Ravensberg J, et coll. Discontinuation of Levothyroxine in Adults Aged 60 Years or Older. JAMA. 2026 Apr 6;335(17):1491–8.</a></p> <p><a href="https://www.apesquebec.org/system/files?file=2025-10/20250930_RPEN_Fiches_ISRA.pdf" target="_blank" rel="noreferrer noopener">RPE de néphrologie de l’APES. Place des IECA et des ARA dans le traitement de la maladie rénale chronique. Septembre 2025.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/36326117/" target="_blank" rel="noreferrer noopener">Bhandari S, et coll; STOP ACEi Trial Investigators. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022 Dec 1;387(22):2021-2032.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/27927602/" target="_blank" rel="noreferrer noopener">Clase CM, et coll. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017;91:683-90.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/30646338/" target="_blank" rel="noreferrer noopener">Garlo KG, et coll. Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease. JAMA Netw Open 2018;1:e183874.</a></p> <p><a href="https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/VRAYLAR_PM_EN.pdf" target="_blank" rel="noreferrer noopener">Monographie de produit, Abbvie. VRAYLAR (cariprazine). Canada, 6 mars 2024.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/40732284/" target="_blank" rel="noreferrer noopener">Barabassy A, et coll. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/28185672/" target="_blank" rel="noreferrer noopener">Németh G, et coll. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 Mar 18;389(10074):1103-1113.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/30045066/" target="_blank" rel="noreferrer noopener">Fava M, et coll. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018 Nov;33(6):312-321.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/28185672/" target="_blank" rel="noreferrer noopener">Durgam S, et coll. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016 Mar;77(3):371-8.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/40732284/" target="_blank" rel="noreferrer noopener">Barabassy A, Csehi R, Dombi ZB, Szatmári B, Brevig T, Németh G. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/35582188/" target="_blank" rel="noreferrer noopener">Zhang J, et coll. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Kidney360. 2022 Jan 19;3(3):477-487.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/31375422/" target="_blank" rel="noreferrer noopener">Toto RD, et coll. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. J Diabetes Complications. 2019 Oct;33(10):107402.</a></p>
May 22, 2026
Épisode 177 – Cholestérol: toujours plus bas?
<p>Un nouvel épisode du Pharmascope est disponible! Dans ce 177e épisode, Nicolas, Olivier et Amélie discutent de cholestérol, des nouvelles lignes directrices de l’AHA sur la dyslipidémie et de l’étude Ez-PAVE.</p> <p>Les objectifs pour cet épisode sont les suivants:</p> <ul class="wp-block-list"> <li>Discuter des nouvelles lignes directrices de l’AHA sur la dyslipidémie </li> <li>Discuter de la littérature entourant les cibles de LDL </li> <li>Discuter de l’étude EZ-PAVE sur l’objectif de viser une cible de LDL inférieure à 1.4 mmol/L</li> </ul> <div style="height:86px" aria-hidden="true" class="wp-block-spacer"></div> <p><strong>Ressources pertinentes en lien avec l’épisode</strong></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/41824590/" target="_blank" rel="noreferrer noopener">Blumenthal RS, et coll. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 May 19;87(19):2624-2757.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/27673306/" target="_blank" rel="noreferrer noopener">Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27;316(12):1289-97.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/17984165/" target="_blank" rel="noreferrer noopener">Barter PJ, et coll; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 Nov 22;357(21):2109-22.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/12114036/" target="_blank" rel="noreferrer noopener">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/31738483/" target="_blank" rel="noreferrer noopener">Amarenco P, et coll; Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020 Jan 2;382(1):9.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/36877807/" target="_blank" rel="noreferrer noopener">Hong SJ, et coll; LODESTAR Investigators. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023 Apr 4;329(13):1078-1087.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/41910315/">Lee YJ, et coll; Ez-PAVE Investigators. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med. 2026 Ap</a><a href="https://pubmed.ncbi.nlm.nih.gov/41910315/" target="_blank" rel="noreferrer noopener">r</a><a href="https://pubmed.ncbi.nlm.nih.gov/41910315/"> 9;394(14):1365-1375.</a></p>
April 28, 2026
Épisode 176 – PreParez-vous aux nouvelles PreP!
<p>Un nouvel épisode du Pharmascope est disponible! Dans ce 176e épisode, Nicolas, Olivier et Amélie discutent de VIH et de PrEP injectable. </p> <p>Les objectifs pour cet épisode sont les suivants:</p> <ul class="wp-block-list"> <li>Identifier les patients pouvant bénéficier de la PrEP</li> <li>Discuter des avantages et des désavantages du cabotégravir</li> <li>Discuter des avantages et des désavantages associés du lénacapavir</li> </ul> <div style="height:84px" aria-hidden="true" class="wp-block-spacer"></div> <p><strong>Ressources pertinentes en lien avec l’épisode</strong></p> <p><a href="https://publications.msss.gouv.qc.ca/msss/fichiers/2018/18-334-02W.pdf" target="_blank" rel="noreferrer noopener">Baril JG et coll. La prophylaxie préexposition au virus de l’immunodéficience humaine : Guide pour les professionnels de la santé du Québec. Ministère de la santé et des services sociaux. Janvier 2019.</a></p> <p><a href="https://pdf.hres.ca/dpd_pm/00075775.PDF" target="_blank" rel="noreferrer noopener">Monographie de produit. Apretude (cabotégravir). Canada. 10 mai 2024.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/34379922" target="_blank" rel="noreferrer noopener">Landovitz RJ, et coll; HPTN 083 Study Team. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 Aug 12;385(7):595-608.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/35378077" target="_blank" rel="noreferrer noopener">Delany-Moretlwe S, et coll; HPTN 084 study group. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 May 7;399(10337):1779-1789.</a></p> <p><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf" target="_blank" rel="noreferrer noopener">Monographie de produit. Yeztugo (lenacapavir). USA. 06/2025.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/39046157" target="_blank" rel="noreferrer noopener">Bekker LG, et coll; PURPOSE 1 Study Team. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024 Oct 3;391(13):1179-1192.</a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/39602624" target="_blank" rel="noreferrer noopener">Kelley CF, et coll; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276.</a></p>
55 total episodes available
Recent guests on Pharmascope
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
invited guest
Guest
Similar Podcasts
Discover related shows you might enjoy
TRAIT PHARMACIEN
A.P.E.S.
Sans Filtre Podcast
Studio SF
Sexe Oral
Lysandre Nadeau, Joanie Grenier
Tout le monde s'haït
Marylène Gendron & Sam Cyr
La vie sociale
La vie sociale
Elles - Le balado
Marilou et Catherine
Ça va maman
La psychologue Dre Lory Zephyr et la journaliste Jessika Brazeau
Minutes pharmacie de l'AQPP
Association québécoise des pharmaciens propriétaires (AQPP)
OUBLIE PAS TA BROSSE À DENTS - Podcast d’Alexandre Barrette
Alexandre Barrette
Ouvre ton jeu avec Marie-Claude Barrette
Umano Productions
Datestable
Vanessa Duchel
En privé SVP
Girl Crush
On s'connait pas tant que ça
Studio SF
Upika Podcast
Studio SF
Mike Ward Sous Écoute
Mike Ward
Deep-dive analytics for Pharmascope
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Pharmascope?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.